Vericel (VCEL) Non-Current Debt (2010 - 2018)
Vericel (VCEL) posted Non-Current Debt of $13.2 million for Q3 2018, down 8.55% sequentially from $14.4 million in Q2 2018, and up 78.15% YoY from $7.4 million in Q3 2017.
Vericel (VCEL) Non-Current Debt (2010 - 2018) Analysis & Trends
Vericel has reported Non-Current Debt for 9 years, with the latest figure at $13.2 million in Q3 2018.
- Quarterly Non-Current Debt rose 78.15% year-over-year to $13.2 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $13.2 million (up 78.15% YoY) and the FY2017 annual result came in at $16.9 million, up 52675.0% from the prior year.
- Non-Current Debt slipped to $13.2 million in Q3 2018 per VCEL's latest filing, from $14.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $16.9 million in Q4 2017 and troughed at $32000.0 in Q4 2016.
- A 5-year average of $5.0 million and a median of $109000.0 in 2014 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2016 and 2017: Non-Current Debt slumped 54.93% in 2016, then soared 52675.0% in 2017.
- Over 5 years, Non-Current Debt stood at $109000.0 in 2014, then tumbled by 34.86% to $71000.0 in 2015, then slumped by 54.93% to $32000.0 in 2016, then jumped by 52675.0% to $16.9 million in 2017, then dropped by 21.94% to $13.2 million in 2018.
- According to Business Quant data, Non-Current Debt over the past three periods registered $13.2 million, $14.4 million, and $15.6 million for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 13.18 Mn |
| Jun 30, 2018 | 14.42 Mn |
| Mar 31, 2018 | 15.65 Mn |
| Dec 31, 2017 | 16.89 Mn |
| Sep 30, 2017 | 7.40 Mn |
| Jun 30, 2017 | 8.04 Mn |
| Mar 31, 2017 | 8.68 Mn |
| Dec 31, 2016 | 32,000.00 |
| Sep 30, 2016 | 42,000.00 |
| Jun 30, 2016 | 52,000.00 |
| Mar 31, 2016 | 62,000.00 |
| Dec 31, 2015 | 71,000.00 |
| Sep 30, 2015 | 81,000.00 |
| Jun 30, 2015 | 91,000.00 |
| Mar 31, 2015 | 100,000.00 |
| Dec 31, 2014 | 109,000.00 |
| Sep 30, 2014 | 115,000.00 |
| Mar 31, 2013 | 2,000.00 |
| Dec 31, 2012 | 6,000.00 |
| Sep 30, 2012 | 9,000.00 |